GNH USA

Europe — EMA

Mresvia

GNH USA supplies Mresvia (mRNA-1345), a vaccine for prevention of respiratory syncytial virus infection. Request a quote for supply to hospitals and clinics.

Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In

Request sourcing

1
Pack/s

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

mRNA-1345, the active ingredient in Mresvia, is a vaccine presented as a solution for injection for intramuscular use. It encodes a stabilized RSV F glycoprotein to stimulate an immune response and is indicated for the prevention of respiratory syncytial virus infection in at‑risk individuals such as infants, older adults, and immunocompromised patients.

GNH USA supplies Mresvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this RSV vaccine for global health programs.

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In used for?

Mresvia is a vaccine that targets respiratory syncytial virus (RSV) infection.

Infants: prevention of severe RSV disease and hospitalization. Older adults: reduction of RSV‑related lower respiratory tract illness. Immunocompromised patients: protection against RSV infection in high‑risk groups.

What are the side effects of Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Mresvia is generally well tolerated, but injection‑related reactions and systemic events can occur.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate headache within 24 hours. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Myocarditis or pericarditis: inflammation of heart muscle or surrounding tissue. - Guillain‑Barré syndrome: rare autoimmune neuropathy. - Severe allergic reaction to any excipient. - Thrombotic events: extremely rare clotting disorders.

What precautions apply to Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Prior to administration, consider the following safety measures.

Screen for severe allergic reactions: avoid use in individuals with known hypersensitivity to any component. Pregnancy: consult a healthcare provider; safety data are limited. Immunocompromised patients: evaluate risk‑benefit ratio before vaccination. Concurrent vaccines: follow recommended intervals to avoid interference. Observe after injection: monitor for immediate adverse reactions for at least 15 minutes. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In interact with?

Vaccines may interact with other therapies; review the following.

Major Interactions (Avoid): - Live attenuated vaccines: avoid concurrent administration due to potential interference. - Known severe allergy to any vaccine component: contraindicated.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: may reduce vaccine efficacy, consider timing. - Antipyretics taken before vaccination: could blunt antibody response, monitor effect. - Seasonal influenza vaccine: can be administered sequentially, ensure appropriate interval.

Frequently asked questions

What is Mresvia used for?+
Mresvia is a vaccine indicated for the prevention of respiratory syncytial virus (RSV) infection. It is designed to protect at‑risk populations such as infants, older adults, and immunocompromised individuals by stimulating an immune response against the RSV F glycoprotein.
How does the active ingredient mRNA-1345 work?+
mRNA-1345 is a single‑stranded, 5' capped messenger RNA that encodes a stabilized form of the RSV F glycoprotein. After intramuscular injection, host cells translate the mRNA into the viral protein, which is then recognized by the immune system, leading to the production of neutralising antibodies and cellular immunity that protect against RSV.
What is the usual dose of Mresvia?+
The dose of Mresvia is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. The prescriber will select the appropriate volume and schedule for each individual.
Is Mresvia safe to use during pregnancy or breastfeeding?+
Safety data for Mresvia in pregnant or breastfeeding individuals are limited. Healthcare providers should weigh the potential benefits against any unknown risks and discuss the decision with the patient. Consultation with a specialist is recommended before vaccination in these populations.
How do I order Mresvia from GNH USA?+
To order Mresvia, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, cold‑chain shipping details, and any necessary import documentation.
How does Mresiva compare with other RSV vaccines?+
Mresvia uses an mRNA platform that delivers the RSV F antigen directly to host cells, whereas many existing RSV vaccines rely on protein subunits or live‑attenuated viruses. The mRNA approach can induce both strong antibody and T‑cell responses and may offer manufacturing flexibility, but comparative effectiveness depends on clinical trial data and population specifics.
What are the storage and handling requirements for Mresvia?+
Mresvia must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, follow the product’s stability guidelines before use.
How is Mresvia administered?+
Mresvia is administered as a single intramuscular injection, typically into the deltoid muscle. The injection is performed by a qualified healthcare professional using aseptic technique. The exact volume and site are determined by the prescriber according to approved labeling.
What are the most serious risks associated with Mresvia?+
The most serious risks include severe allergic reactions such as anaphylaxis, myocarditis or pericarditis, and rare neurological events like Guillain‑Barré syndrome. Patients should be observed for at least 15 minutes after vaccination, and any signs of a serious reaction require immediate medical attention.
Who should not receive Mresvia?+
Mresvia should not be given to individuals with a known severe allergy to any component of the vaccine. It is also contraindicated in patients who have experienced a serious immediate hypersensitivity reaction to a previous dose of the same vaccine. Clinicians should assess each patient’s medical history before administration.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In
Route
Intramuscular Use
Manufacturer
Moderna Biotech Spain S. L.
Origin
EU